HRP920170A2 - New selective aromatase inhibiting 4(5) imidazoles - Google Patents
New selective aromatase inhibiting 4(5) imidazoles Download PDFInfo
- Publication number
- HRP920170A2 HRP920170A2 HR920170A HRP920170A HRP920170A2 HR P920170 A2 HRP920170 A2 HR P920170A2 HR 920170 A HR920170 A HR 920170A HR P920170 A HRP920170 A HR P920170A HR P920170 A2 HRP920170 A2 HR P920170A2
- Authority
- HR
- Croatia
- Prior art keywords
- imidazole
- compound according
- cyanophenyl
- pharmaceutically acceptable
- acid addition
- Prior art date
Links
- 102000014654 Aromatase Human genes 0.000 title claims description 11
- 108010078554 Aromatase Proteins 0.000 title claims description 11
- 230000002401 inhibitory effect Effects 0.000 title claims description 7
- 150000002460 imidazoles Chemical class 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 156
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 38
- 239000002253 acid Substances 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 31
- 231100000252 nontoxic Toxicity 0.000 claims description 28
- 230000003000 nontoxic effect Effects 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 13
- 230000005764 inhibitory process Effects 0.000 claims description 12
- MRBWTJWBRJOYOB-UHFFFAOYSA-N 4-[3-(4-fluorophenyl)-1-(1h-imidazol-5-yl)prop-1-enyl]benzonitrile Chemical group C1=CC(F)=CC=C1CC=C(C=1C=CC(=CC=1)C#N)C1=CNC=N1 MRBWTJWBRJOYOB-UHFFFAOYSA-N 0.000 claims description 8
- JHAPQEPKKUPGAA-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1-(1h-imidazol-5-yl)butyl]benzonitrile Chemical group C1=CC(F)=CC=C1CCCC(C=1C=CC(=CC=1)C#N)C1=CNC=N1 JHAPQEPKKUPGAA-UHFFFAOYSA-N 0.000 claims description 8
- KOTPKKGZQNWBBV-UHFFFAOYSA-N 4-[4-(4-fluorophenyl)-1-(1h-imidazol-5-yl)but-1-enyl]benzonitrile Chemical group C1=CC(F)=CC=C1CCC=C(C=1C=CC(=CC=1)C#N)C1=CNC=N1 KOTPKKGZQNWBBV-UHFFFAOYSA-N 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- VZCAGYHHFBPDOY-UHFFFAOYSA-N 4-[3-(1h-imidazol-5-yl)-1-phenylpropyl]benzonitrile Chemical group C1=CC(C#N)=CC=C1C(C=1C=CC=CC=1)CCC1=CNC=N1 VZCAGYHHFBPDOY-UHFFFAOYSA-N 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 5
- DTDSUERYHSVJKB-UHFFFAOYSA-N 4-[1-(4-fluorophenyl)-3-(1h-imidazol-5-yl)propyl]benzonitrile Chemical group C1=CC(F)=CC=C1C(C=1C=CC(=CC=1)C#N)CCC1=CNC=N1 DTDSUERYHSVJKB-UHFFFAOYSA-N 0.000 claims description 4
- ZIRXFAIJRWJWSD-UHFFFAOYSA-N 4-[3-(4-fluorophenyl)-3-(1h-imidazol-5-yl)prop-2-enyl]benzonitrile Chemical group C1=CC(F)=CC=C1C(C=1N=CNC=1)=CCC1=CC=C(C#N)C=C1 ZIRXFAIJRWJWSD-UHFFFAOYSA-N 0.000 claims description 4
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010081348 HRT1 protein Hairy Proteins 0.000 claims description 4
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 claims description 4
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- LYVUWAIDQCZNCU-UHFFFAOYSA-N 4-[1-(1h-imidazol-5-yl)-4-phenylbutyl]benzonitrile Chemical group C1=CC(C#N)=CC=C1C(C=1N=CNC=1)CCCC1=CC=CC=C1 LYVUWAIDQCZNCU-UHFFFAOYSA-N 0.000 claims description 3
- ORSRGXAFGYIAPU-UHFFFAOYSA-N 4-[1-(4-cyanophenyl)-4-(1h-imidazol-5-yl)butyl]benzonitrile Chemical group C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)CCCC1=CNC=N1 ORSRGXAFGYIAPU-UHFFFAOYSA-N 0.000 claims description 3
- KSEMPMZBYRFSJA-UHFFFAOYSA-N 4-[3-(1h-imidazol-5-yl)-1-[4-(trifluoromethyl)phenyl]propyl]benzonitrile Chemical group C1=CC(C(F)(F)F)=CC=C1C(C=1C=CC(=CC=1)C#N)CCC1=CNC=N1 KSEMPMZBYRFSJA-UHFFFAOYSA-N 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- SVTAFOMBFGRXGF-UHFFFAOYSA-N 4-[1-(4-cyanophenyl)-3-(1h-imidazol-5-yl)prop-1-enyl]benzonitrile Chemical group C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC1=CNC=N1 SVTAFOMBFGRXGF-UHFFFAOYSA-N 0.000 claims description 2
- QMXMKKNXGMAESN-UHFFFAOYSA-N 4-[3-(1h-imidazol-5-yl)-1-(4-methoxyphenyl)propyl]benzonitrile Chemical group C1=CC(OC)=CC=C1C(C=1C=CC(=CC=1)C#N)CCC1=CNC=N1 QMXMKKNXGMAESN-UHFFFAOYSA-N 0.000 claims description 2
- MSCKCBLDSVUTNB-UHFFFAOYSA-N 4-[4-(4-cyanophenyl)-4-(1h-imidazol-5-yl)but-3-enyl]benzonitrile Chemical group C1=CC(C#N)=CC=C1CCC=C(C=1C=CC(=CC=1)C#N)C1=CNC=N1 MSCKCBLDSVUTNB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- MNQBLSZOYGNSPV-UHFFFAOYSA-N 4-[1-(4-fluorophenyl)-3-(1h-imidazol-5-yl)prop-1-enyl]benzonitrile Chemical group C1=CC(F)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC1=CNC=N1 MNQBLSZOYGNSPV-UHFFFAOYSA-N 0.000 claims 1
- WJGZRAWVMPHHAN-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-1-(4-cyanophenyl)prop-1-enyl]benzonitrile Chemical group C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC1=CN=CN1CC1=CC=CC=C1 WJGZRAWVMPHHAN-UHFFFAOYSA-N 0.000 claims 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 81
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 78
- 238000005160 1H NMR spectroscopy Methods 0.000 description 62
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 52
- 239000000243 solution Substances 0.000 description 37
- 239000000203 mixture Substances 0.000 description 35
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 28
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 27
- 150000003840 hydrochlorides Chemical class 0.000 description 26
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- -1 alkyl lithium Chemical compound 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 19
- 238000005984 hydrogenation reaction Methods 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 12
- 239000011777 magnesium Substances 0.000 description 12
- 229910052749 magnesium Inorganic materials 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 229940011871 estrogen Drugs 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 238000006276 transfer reaction Methods 0.000 description 7
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 6
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 229910052744 lithium Inorganic materials 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 6
- 125000003504 2-oxazolinyl group Chemical group O1C(=NCC1)* 0.000 description 5
- QONDAZCJAPQGRX-UHFFFAOYSA-N 3-benzylimidazole-4-carbaldehyde Chemical compound O=CC1=CN=CN1CC1=CC=CC=C1 QONDAZCJAPQGRX-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229910052721 tungsten Inorganic materials 0.000 description 5
- RRBQRILCDBHUHU-UHFFFAOYSA-N 1-(3-benzylimidazol-4-yl)-4-(4-fluorophenyl)butan-1-ol Chemical compound C=1N=CN(CC=2C=CC=CC=2)C=1C(O)CCCC1=CC=C(F)C=C1 RRBQRILCDBHUHU-UHFFFAOYSA-N 0.000 description 4
- SBGSFCBQZBIKCL-UHFFFAOYSA-N 1-(3-benzylimidazol-4-yl)-4-(4-fluorophenyl)butan-1-one Chemical compound C1=CC(F)=CC=C1CCCC(=O)C1=CN=CN1CC1=CC=CC=C1 SBGSFCBQZBIKCL-UHFFFAOYSA-N 0.000 description 4
- SZBIOYUSHZRXMD-UHFFFAOYSA-N 4-[1-(4-cyanophenyl)-3-(1h-imidazol-5-yl)propyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)CCC1=CNC=N1 SZBIOYUSHZRXMD-UHFFFAOYSA-N 0.000 description 4
- ARSRBNBHOADGJU-UHFFFAOYSA-N 7,12-dimethyltetraphene Chemical compound C1=CC2=CC=CC=C2C2=C1C(C)=C(C=CC=C1)C1=C2C ARSRBNBHOADGJU-UHFFFAOYSA-N 0.000 description 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 4
- VFZRZRDOXPRTSC-UHFFFAOYSA-N DMBA Natural products COC1=CC(OC)=CC(C=O)=C1 VFZRZRDOXPRTSC-UHFFFAOYSA-N 0.000 description 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229910006124 SOCl2 Inorganic materials 0.000 description 4
- 238000005882 aldol condensation reaction Methods 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 102000004317 Lyases Human genes 0.000 description 3
- 108090000856 Lyases Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- ZLIAGYVFHDVPCS-UHFFFAOYSA-N 1-(3-benzylimidazol-4-yl)-4-phenylbutan-1-ol Chemical compound C=1N=CN(CC=2C=CC=CC=2)C=1C(O)CCCC1=CC=CC=C1 ZLIAGYVFHDVPCS-UHFFFAOYSA-N 0.000 description 2
- QPBMWTZOORQTCX-UHFFFAOYSA-N 1-(3-benzylimidazol-4-yl)-4-phenylbutan-1-one Chemical compound C=1N=CN(CC=2C=CC=CC=2)C=1C(=O)CCCC1=CC=CC=C1 QPBMWTZOORQTCX-UHFFFAOYSA-N 0.000 description 2
- BLQNOZHGIDFFAS-UHFFFAOYSA-N 1-(3-benzylimidazol-4-yl)ethanone Chemical compound CC(=O)C1=CN=CN1CC1=CC=CC=C1 BLQNOZHGIDFFAS-UHFFFAOYSA-N 0.000 description 2
- SCVWLBZEYMAAHN-UHFFFAOYSA-N 1-(3-bromopropyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCCBr)C=C1 SCVWLBZEYMAAHN-UHFFFAOYSA-N 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- PLWLLYFZXKQRDJ-UHFFFAOYSA-N 4-[1-(3-benzylimidazol-4-yl)-3-(4-fluorophenyl)-1-hydroxypropyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1N(C=NC=1)CC=1C=CC=CC=1)CCC1=CC=C(F)C=C1 PLWLLYFZXKQRDJ-UHFFFAOYSA-N 0.000 description 2
- DSILKXQWUWDIKI-UHFFFAOYSA-N 4-[3-(1h-imidazol-5-yl)-1-[4-(trifluoromethyl)phenyl]prop-1-enyl]benzonitrile Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC1=CN=CN1 DSILKXQWUWDIKI-UHFFFAOYSA-N 0.000 description 2
- FZMGMDLGMVXWCF-UHFFFAOYSA-N 4-bromo-n-tert-butylbenzamide Chemical compound CC(C)(C)NC(=O)C1=CC=C(Br)C=C1 FZMGMDLGMVXWCF-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 101000919395 Homo sapiens Aromatase Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- CYTYCFOTNPOANT-UHFFFAOYSA-N Perchloroethylene Chemical group ClC(Cl)=C(Cl)Cl CYTYCFOTNPOANT-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 125000001743 benzylic group Chemical group 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000006193 diazotization reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 102000044018 human CYP19A1 Human genes 0.000 description 2
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- SYTPXAXERSBEQM-UHFFFAOYSA-N n-tert-butyl-4-[3-(4-fluorophenyl)-3-hydroxy-3-(1h-imidazol-5-yl)propyl]benzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1CCC(O)(C=1C=CC(F)=CC=1)C1=CNC=N1 SYTPXAXERSBEQM-UHFFFAOYSA-N 0.000 description 2
- YFLBUUWWEGBOKW-UHFFFAOYSA-N n-tert-butyl-4-[4-(4-fluorophenyl)-1-hydroxy-1-(1h-imidazol-5-yl)butyl]benzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1N=CNC=1)CCCC1=CC=C(F)C=C1 YFLBUUWWEGBOKW-UHFFFAOYSA-N 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 238000006396 nitration reaction Methods 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229960000249 pregnenolone Drugs 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229950011008 tetrachloroethylene Drugs 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- HXRVTZVVSGPFEC-BTJKTKAUSA-N (z)-but-2-enedioic acid;2,3-dihydroxybutanedioic acid Chemical class OC(=O)\C=C/C(O)=O.OC(=O)C(O)C(O)C(O)=O HXRVTZVVSGPFEC-BTJKTKAUSA-N 0.000 description 1
- AOGCMZFSDDPNHF-UHFFFAOYSA-N 1-(3-benzylimidazol-4-yl)-3-(4-fluorophenyl)propan-1-one Chemical compound C1=CC(F)=CC=C1CCC(=O)C1=CN=CN1CC1=CC=CC=C1 AOGCMZFSDDPNHF-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- CTRDSFKKHKXNPE-UHFFFAOYSA-N 2-[4-(2-carboxyphenyl)-4-(1h-imidazol-5-yl)but-3-enyl]benzoic acid;hydrochloride Chemical compound Cl.OC(=O)C1=CC=CC=C1CCC=C(C=1C(=CC=CC=1)C(O)=O)C1=CN=CN1 CTRDSFKKHKXNPE-UHFFFAOYSA-N 0.000 description 1
- KFPYJDFCCSYVNW-UHFFFAOYSA-N 3-(3-benzylimidazol-4-yl)-1-phenylpropan-1-one Chemical compound C=1C=CC=CC=1C(=O)CCC1=CN=CN1CC1=CC=CC=C1 KFPYJDFCCSYVNW-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- YNROJSQZXHMZHN-UHFFFAOYSA-N 4-[1-(3-benzylimidazol-4-yl)-4-(4-fluorophenyl)-1-hydroxybutyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1N(C=NC=1)CC=1C=CC=CC=1)CCCC1=CC=C(F)C=C1 YNROJSQZXHMZHN-UHFFFAOYSA-N 0.000 description 1
- FABFRAINHLPLRL-UHFFFAOYSA-N 4-[1-(3-benzylimidazol-4-yl)-4-(4-fluorophenyl)-1-hydroxybutyl]-n-tert-butylbenzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1N(C=NC=1)CC=1C=CC=CC=1)CCCC1=CC=C(F)C=C1 FABFRAINHLPLRL-UHFFFAOYSA-N 0.000 description 1
- PPNJFKNCGZLKGR-UHFFFAOYSA-N 4-[1-(3-benzylimidazol-4-yl)-4-phenylbut-1-enyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=1N(C=NC=1)CC=1C=CC=CC=1)=CCCC1=CC=CC=C1 PPNJFKNCGZLKGR-UHFFFAOYSA-N 0.000 description 1
- WLFFXICNBRNWAN-UHFFFAOYSA-N 4-[1-(3-benzylimidazol-4-yl)-4-phenylbut-1-enyl]benzonitrile;hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1C(C=1N(C=NC=1)CC=1C=CC=CC=1)=CCCC1=CC=CC=C1 WLFFXICNBRNWAN-UHFFFAOYSA-N 0.000 description 1
- UTEZJICOBLTVPK-UHFFFAOYSA-N 4-[1-(4-cyanophenyl)-3-(1h-imidazol-5-yl)prop-1-enyl]benzonitrile;hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC1=CNC=N1 UTEZJICOBLTVPK-UHFFFAOYSA-N 0.000 description 1
- PJQHOEPUHRWSDM-UHFFFAOYSA-N 4-[3-(1-benzylimidazol-4-yl)-1-(4-cyanophenyl)prop-1-enyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC(N=C1)=CN1CC1=CC=CC=C1 PJQHOEPUHRWSDM-UHFFFAOYSA-N 0.000 description 1
- BFABIPOLAZUIHC-UHFFFAOYSA-N 4-[3-(1-benzylimidazol-4-yl)-1-(4-cyanophenyl)prop-1-enyl]benzonitrile;hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC(N=C1)=CN1CC1=CC=CC=C1 BFABIPOLAZUIHC-UHFFFAOYSA-N 0.000 description 1
- KAQAOZWKTOGXRJ-UHFFFAOYSA-N 4-[3-(1h-imidazol-5-yl)-1-(4-methoxyphenyl)prop-1-enyl]benzonitrile Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC1=CNC=N1 KAQAOZWKTOGXRJ-UHFFFAOYSA-N 0.000 description 1
- HNOUQRGQZYIVCN-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-1-(4-fluorophenyl)prop-1-enyl]benzonitrile Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCC1=CN=CN1CC1=CC=CC=C1 HNOUQRGQZYIVCN-UHFFFAOYSA-N 0.000 description 1
- ATQFCTQCDSDQGB-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-1-hydroxy-1-(4-methoxyphenyl)propyl]-n-tert-butylbenzamide Chemical compound C1=CC(OC)=CC=C1C(O)(C=1C=CC(=CC=1)C(=O)NC(C)(C)C)CCC1=CN=CN1CC1=CC=CC=C1 ATQFCTQCDSDQGB-UHFFFAOYSA-N 0.000 description 1
- SMLJJWMPOAGXOG-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-1-hydroxy-1-[4-(trifluoromethyl)phenyl]propyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)C(F)(F)F)CCC1=CN=CN1CC1=CC=CC=C1 SMLJJWMPOAGXOG-UHFFFAOYSA-N 0.000 description 1
- JIYFHSFQEPHGNZ-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-1-hydroxy-1-phenylpropyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1C=CC=CC=1)CCC1=CN=CN1CC1=CC=CC=C1 JIYFHSFQEPHGNZ-UHFFFAOYSA-N 0.000 description 1
- YNHWQLANBSERKE-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-1-phenylprop-1-enyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=1C=CC=CC=1)=CCC1=CN=CN1CC1=CC=CC=C1 YNHWQLANBSERKE-UHFFFAOYSA-N 0.000 description 1
- ARWNZTMXFIWWFL-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-1-phenylprop-1-enyl]benzonitrile;hydrochloride Chemical compound Cl.C1=CC(C#N)=CC=C1C(C=1C=CC=CC=1)=CCC1=CN=CN1CC1=CC=CC=C1 ARWNZTMXFIWWFL-UHFFFAOYSA-N 0.000 description 1
- ITERAUXAKDXMAX-UHFFFAOYSA-N 4-[3-(3-benzylimidazol-4-yl)-3-(4-fluorophenyl)-3-hydroxypropyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1CCC(O)(C=1C=CC(F)=CC=1)C1=CN=CN1CC1=CC=CC=C1 ITERAUXAKDXMAX-UHFFFAOYSA-N 0.000 description 1
- LPCYSBIWTXIZFD-UHFFFAOYSA-N 4-[4-(3-benzylimidazol-4-yl)-1-(4-cyanophenyl)but-1-enyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1C(C=1C=CC(=CC=1)C#N)=CCCC1=CN=CN1CC1=CC=CC=C1 LPCYSBIWTXIZFD-UHFFFAOYSA-N 0.000 description 1
- AZNNIEFARSBBBR-UHFFFAOYSA-N 4-[4-(3-benzylimidazol-4-yl)-1-[4-(tert-butylcarbamoyl)phenyl]-1-hydroxybutyl]-n-tert-butylbenzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)C(=O)NC(C)(C)C)CCCC1=CN=CN1CC1=CC=CC=C1 AZNNIEFARSBBBR-UHFFFAOYSA-N 0.000 description 1
- UMLBUSXGDLPYJJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)-4-(1h-imidazol-5-yl)but-3-enyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1CCC=C(C=1C=CC(=CC=1)C(O)=O)C1=CNC=N1 UMLBUSXGDLPYJJ-UHFFFAOYSA-N 0.000 description 1
- ALUSULHZSGPXNX-UHFFFAOYSA-N 4-[4-(4-cyanophenyl)-4-(1h-imidazol-5-yl)butyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CCCC(C=1C=CC(=CC=1)C#N)C1=CNC=N1 ALUSULHZSGPXNX-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- QIUNMSWQLOLJBK-UHFFFAOYSA-N C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)C(=O)NC(C)(C)C)CCC1=CN=CN1 Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1C=CC(=CC=1)C(=O)NC(C)(C)C)CCC1=CN=CN1 QIUNMSWQLOLJBK-UHFFFAOYSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- GTBRTGPZZALPNS-MXHVRSFHSA-N cyanoketone Chemical compound C1C=C2C(C)(C)C(=O)[C@H](C#N)C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GTBRTGPZZALPNS-MXHVRSFHSA-N 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- JSWPRMWAPSFWKG-UHFFFAOYSA-N ethyl 3-(1-benzylimidazol-4-yl)propanoate Chemical compound C1=NC(CCC(=O)OCC)=CN1CC1=CC=CC=C1 JSWPRMWAPSFWKG-UHFFFAOYSA-N 0.000 description 1
- BHYVHYPBRYOMGC-UHFFFAOYSA-N ethyl 4-formylbenzoate Chemical compound CCOC(=O)C1=CC=C(C=O)C=C1 BHYVHYPBRYOMGC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003324 growth hormone secretagogue Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- LKFQZJFOELEYDS-UHFFFAOYSA-N n-tert-butyl-4-[1-(4-fluorophenyl)-1-hydroxy-3-(1h-imidazol-5-yl)propyl]benzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1C=CC(F)=CC=1)CCC1=CNC=N1 LKFQZJFOELEYDS-UHFFFAOYSA-N 0.000 description 1
- XJZZGZRPJZAFNQ-UHFFFAOYSA-N n-tert-butyl-4-[1-hydroxy-3-(1h-imidazol-5-yl)-1-(4-methoxyphenyl)propyl]benzamide Chemical compound C1=CC(OC)=CC=C1C(O)(C=1C=CC(=CC=1)C(=O)NC(C)(C)C)CCC1=CNC=N1 XJZZGZRPJZAFNQ-UHFFFAOYSA-N 0.000 description 1
- HPJAEPCUJHMKFS-UHFFFAOYSA-N n-tert-butyl-4-[1-hydroxy-3-(1h-imidazol-5-yl)-1-phenylpropyl]benzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1C=CC=CC=1)CCC1=CNC=N1 HPJAEPCUJHMKFS-UHFFFAOYSA-N 0.000 description 1
- ORCZGNDLWQBPHS-UHFFFAOYSA-N n-tert-butyl-4-[3-(1h-imidazol-5-yl)-1-phenylprop-1-enyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NC(C)(C)C)=CC=C1C(C=1C=CC=CC=1)=CCC1=CNC=N1 ORCZGNDLWQBPHS-UHFFFAOYSA-N 0.000 description 1
- JZJRCTXRFYSHPA-UHFFFAOYSA-N n-tert-butyl-4-[3-(4-fluorophenyl)-1-hydroxy-1-(1h-imidazol-5-yl)propyl]benzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(O)(C=1N=CNC=1)CCC1=CC=C(F)C=C1 JZJRCTXRFYSHPA-UHFFFAOYSA-N 0.000 description 1
- LRSXTIFSTNTZRV-UHFFFAOYSA-N n-tert-butyl-4-[4-(4-fluorophenyl)-1-(1h-imidazol-5-yl)butyl]benzamide Chemical compound C1=CC(C(=O)NC(C)(C)C)=CC=C1C(C=1N=CNC=1)CCCC1=CC=C(F)C=C1 LRSXTIFSTNTZRV-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919113142A GB9113142D0 (en) | 1991-06-18 | 1991-06-18 | New selective aromatase inhibiting 4(5)-imidazoles |
| GB919125924A GB9125924D0 (en) | 1991-06-18 | 1991-12-05 | Stereoisomers of an imidazole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP920170A2 true HRP920170A2 (en) | 1994-08-31 |
Family
ID=26299089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR920170A HRP920170A2 (en) | 1991-06-18 | 1992-06-17 | New selective aromatase inhibiting 4(5) imidazoles |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5559141A (fr) |
| EP (1) | EP0589975A1 (fr) |
| JP (1) | JPH06508119A (fr) |
| KR (1) | KR940701386A (fr) |
| CN (1) | CN1068819A (fr) |
| AU (1) | AU665002B2 (fr) |
| BG (1) | BG98306A (fr) |
| CA (1) | CA2111469A1 (fr) |
| CZ (1) | CZ280293A3 (fr) |
| FI (1) | FI935658A0 (fr) |
| GB (1) | GB9125924D0 (fr) |
| HR (1) | HRP920170A2 (fr) |
| HU (1) | HUT67325A (fr) |
| IE (1) | IE921963A1 (fr) |
| IL (2) | IL102216A (fr) |
| LT (1) | LT3164B (fr) |
| LV (1) | LV10093B (fr) |
| MX (1) | MX9203000A (fr) |
| NO (1) | NO934688D0 (fr) |
| NZ (1) | NZ243139A (fr) |
| PT (1) | PT100604A (fr) |
| SI (1) | SI9200113A (fr) |
| SK (1) | SK144393A3 (fr) |
| TW (1) | TW206217B (fr) |
| WO (1) | WO1992022537A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2273704B (en) * | 1992-12-16 | 1997-01-22 | Orion Yhtymae Oy | Triazolyl diaryl selective aromatase inhibiting compounds |
| SE9302333D0 (sv) * | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
| US6063930A (en) * | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| CA2250231A1 (fr) * | 1996-04-03 | 1997-10-09 | Robert P. Gomez | Inhibiteurs de la farnesyl-proteine transferase |
| US6080870A (en) * | 1996-04-03 | 2000-06-27 | Merck & Co., Inc. | Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
| US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| CA2416946A1 (fr) | 2000-07-28 | 2003-01-22 | Sumitomo Pharmaceuticals Co., Ltd. | Derives du pyrrole |
| EP1680109A4 (fr) | 2003-10-07 | 2009-05-06 | Renovis Inc | Derives d'amide utilises comme ligands du canal ionique et compositions pharmaceutiques et methodes d'utilisation de ces derives |
| US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| BRPI0606365A2 (pt) * | 2005-02-28 | 2017-06-27 | Renovis Inc | composto ou um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo e estereoisômeros e tautômeros do mesmo, composição farmacêutica, métodos para prevenir, tratar, melhorar ou controlar uma doença ou condição e para preparar um composto, uso de um composto ou um sal, solvato ou composição farmaceuticamente aceitável do mesmo, método de tratamento de um mamífero, e, combinação |
| US7902247B2 (en) * | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| AU2024263053A1 (en) * | 2023-04-25 | 2025-11-20 | Alpherabio Llc | Imidazole containing compounds, derivatives therefore, and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4605661A (en) * | 1984-06-18 | 1986-08-12 | Eli Lilly And Company | Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles |
| GB2210875B (en) * | 1987-10-09 | 1991-05-29 | Farmos Oy | Aromatase inhibiting 4(5)-imidazoles |
| AU627559B2 (en) * | 1989-03-30 | 1992-08-27 | Farmos-Yhtyma Oy | Novel aromatase inhibiting 4(5)-imidazoles |
| GB2248058B (en) * | 1990-09-21 | 1994-09-14 | Orion Yhtymae Oy | Aromatase inhibiting 4(5)-imidazoles |
| US5439928A (en) * | 1989-03-30 | 1995-08-08 | Orion-Yhtyma Oy | Aromatase inhibiting 4(5)-imidazoles |
-
1991
- 1991-12-05 GB GB919125924A patent/GB9125924D0/en active Pending
-
1992
- 1992-06-12 AU AU19783/92A patent/AU665002B2/en not_active Ceased
- 1992-06-12 JP JP4511061A patent/JPH06508119A/ja active Pending
- 1992-06-12 KR KR1019930703934A patent/KR940701386A/ko not_active Withdrawn
- 1992-06-12 CA CA002111469A patent/CA2111469A1/fr not_active Abandoned
- 1992-06-12 WO PCT/FI1992/000184 patent/WO1992022537A1/fr not_active Ceased
- 1992-06-12 EP EP92912309A patent/EP0589975A1/fr not_active Withdrawn
- 1992-06-12 US US08/167,873 patent/US5559141A/en not_active Expired - Fee Related
- 1992-06-12 CZ CS932802A patent/CZ280293A3/cs unknown
- 1992-06-12 SK SK1443-93A patent/SK144393A3/sk unknown
- 1992-06-15 NZ NZ243139A patent/NZ243139A/en unknown
- 1992-06-15 LV LVP-92-29A patent/LV10093B/en unknown
- 1992-06-16 IL IL10221692A patent/IL102216A/en not_active IP Right Cessation
- 1992-06-17 PT PT100604A patent/PT100604A/pt not_active Application Discontinuation
- 1992-06-17 TW TW081104752A patent/TW206217B/zh active
- 1992-06-17 HR HR920170A patent/HRP920170A2/hr not_active Application Discontinuation
- 1992-06-18 MX MX9203000A patent/MX9203000A/es unknown
- 1992-06-18 CN CN92105664A patent/CN1068819A/zh active Pending
- 1992-06-18 SI SI19929200113A patent/SI9200113A/sl unknown
- 1992-07-01 IE IE196392A patent/IE921963A1/en not_active Application Discontinuation
- 1992-08-28 LT LTIP175A patent/LT3164B/lt not_active IP Right Cessation
-
1993
- 1993-12-16 FI FI935658A patent/FI935658A0/fi not_active Application Discontinuation
- 1993-12-17 BG BG98306A patent/BG98306A/bg unknown
- 1993-12-17 HU HU9303653A patent/HUT67325A/hu active IP Right Revival
- 1993-12-17 NO NO934688A patent/NO934688D0/no unknown
-
1995
- 1995-09-27 IL IL11543995A patent/IL115439A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI935658A7 (fi) | 1993-12-16 |
| IL115439A0 (en) | 1995-12-31 |
| FI935658A0 (fi) | 1993-12-16 |
| JPH06508119A (ja) | 1994-09-14 |
| AU665002B2 (en) | 1995-12-14 |
| US5559141A (en) | 1996-09-24 |
| GB9125924D0 (en) | 1992-02-05 |
| NO934688L (no) | 1993-12-17 |
| LT3164B (en) | 1995-02-27 |
| NO934688D0 (no) | 1993-12-17 |
| EP0589975A1 (fr) | 1994-04-06 |
| LV10093B (en) | 1995-02-20 |
| WO1992022537A1 (fr) | 1992-12-23 |
| BG98306A (bg) | 1994-08-30 |
| SI9200113A (en) | 1992-12-31 |
| LV10093A (lv) | 1994-05-10 |
| AU1978392A (en) | 1993-01-12 |
| NZ243139A (en) | 1994-08-26 |
| KR940701386A (ko) | 1994-05-28 |
| TW206217B (fr) | 1993-05-21 |
| CN1068819A (zh) | 1993-02-10 |
| CA2111469A1 (fr) | 1992-12-23 |
| MX9203000A (es) | 1993-02-01 |
| SK144393A3 (en) | 1994-11-09 |
| IL102216A0 (en) | 1993-01-14 |
| IL102216A (en) | 1996-06-18 |
| IE921963A1 (en) | 1992-12-30 |
| LTIP175A (lt) | 1994-08-25 |
| CZ280293A3 (en) | 1994-05-18 |
| PT100604A (pt) | 1993-10-29 |
| HUT67325A (en) | 1995-03-28 |
| HU9303653D0 (en) | 1994-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5098923A (en) | Aromatase inhibiting 4(5)-imidazoles | |
| US5962495A (en) | Selective aromatase inhibiting compounds | |
| WO2000019994A9 (fr) | Ligands se liant aux recepteurs d'oestrogenes | |
| HRP920170A2 (en) | New selective aromatase inhibiting 4(5) imidazoles | |
| CA1161849A (fr) | Derives de l'indole agissant sur le systeme cardio- vasculaire | |
| EP0390558B1 (fr) | 4(5)-Imidazoles inhibant l'aromatase | |
| US5439928A (en) | Aromatase inhibiting 4(5)-imidazoles | |
| AU640817B2 (en) | Aromatase inhibiting 4(5)-imidazoles | |
| PL162554B1 (pl) | S posób wytwarzania nowych pochodnych imidazolu PL PL PL PL PL | |
| GB2231568A (en) | New aromatase inhibiting 4(5)-imidazoles | |
| NZ238390A (en) | 4,4-bis(trifluoromethyl)imidazolidin-5-one derivatives and pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| OBST | Application withdrawn |